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Whole-tumor apparent diffusion coefficient measurements in nephroblastoma: Can it 
identify blastemal predominance? 
Abstract 
Purpose 
To explore the potential relation between whole-tumor apparent diffusion coefficient (ADC) 
parameters in viable parts of tumor and histopathological findings in nephroblastoma. 
Materials and Methods 
Children (n = 52) with histopathologically proven nephroblastoma underwent diffusion-
weighted magnetic resonance imaging (MRI) (1.5T) before preoperative chemotherapy. Of 
these, 25 underwent an additional MRI after preoperative chemotherapy, shortly before 
resection. An experienced reader performed the whole-tumor ADC measurements of all 
lesions, excluding nonenhancing areas. An experienced pathologist reviewed the 
postoperative specimens according to standard SIOP guidelines. Potential associations 
between ADC parameters and proportions of histological subtypes were assessed with 
Pearson's or Spearman's rank correlation coefficient depending on whether the parameters 
tested were normally distributed. In case the Mann–Whitney U-test revealed significantly 
different ADC values in a subtype tumor, this ADC parameter was used to derive a receiver 
operating characteristic (ROC) curve. 
Results 
The 25th percentile ADC at presentation was the best ADC metric correlated with 
proportion of blastema (Pearson's r = –0.303, P = 0.026). ADC after preoperative treatment 
showed moderate correlation with proportion stromal subtype at histopathology (r = 0.579, 
P = 0.002). By ROC analysis, the optimal threshold of median ADC for detecting stromal 
subtype was 1.362 × 10−3 mm2/s with sensitivity and specificity of 100% (95% confidence 
interval [CI] 0.65–1.00) and 78.9% (95% CI 0.57–0.92), respectively. 
Conclusion 
ADC markers in nephroblastoma are related to stromal subtype histopathology; however, 
identification of blastemal predominant tumors using whole-tumor ADC measurements is 
probably not feasible. 
Level of Evidence 3 
Wilms' tumor (nephroblastoma) is the most common, malignant renal tumor in children.[1-
4] It develops from embryonic kidney cells, containing varying amounts of tissue 
recapitulating stages of renal development, including blastemal, epithelial, and stromal 
components.[1] According to the current International Society of Pediatric Oncology 
guidelines, the treatment in patients over the age of 6 months includes 4–6 weeks' 
preoperative chemotherapy, followed by surgery.[2] Overall, the outcome of patients with 
nephroblastoma is excellent[4] and the current focus is on identifying biological and imaging 
markers to further improve outcomes and reduce therapy-induced long-term sequelae in 
these very young patients.[4] 
Apparent diffusion coefficient (ADC) may be an interesting imaging biomarker for identifying 
high-risk histopathology type nephroblastomas and for assessing treatment response. 
However, the literature on the role of diffusion-weighted imaging (DWI) in nephroblastoma 
is limited. A few studies have identified associations between ADC values and 
histopathological findings in a variety of pediatric extracranial mass lesions.[5-11] 
Humphries et al found a significant relationship between cellularity and ADC value in a 
range of pediatric tumors.[5] Some studies have reported considerable differences in ADC 
value between benign and malignant abdominal mass lesions.[6, 7] McDonald et al 
demonstrated that changes in ADC in pediatric abdominal masses during therapy are 
measurable.[8] A recent preclinical study has reported that with mathematical modeling it is 
possible to identify subtypes of ADC in nephroblastoma.[9] However, the implication of the 
ADC measurements in routine clinical practice has not yet been determined. Therefore, we 
searched for ADC measurements that might provide clinically relevant information in 
patients with nephroblastoma. More specifically, we investigated if whole-tumor ADC 
measurements could help identify high-risk lesions that require intensification of treatment, 
for instance, blastemal predominant tumors. 
The aim of this retrospective explorative study was to investigate specific patterns in ADC 
change during preoperative treatment and to study potential ADC metrics that are related 
to the different histopathological subtypes in nephroblastoma using a previously published 
reproducible method. 
Materials and Methods 
Patients 
The Research Ethics Committee of our institution waived the need for formal ethics 
approval, or informed consent for this retrospective study, and in particular since all 
examinations included in the study were clinically indicated and had been conducted in 
accordance with the normal standard of care in our institution. Great Ormond Street 
Hospital for children is a tertiary referral center for nephroblastoma and a quartiary referral 
center for bilateral nephroblastoma. Between July 2007 and February 2014, 72 consecutive 
children were considered for inclusion. Inclusion criteria were histologically proven 
nephroblastoma, treatment according to the SIOP-RT 2001 protocol (preoperative 
treatment followed by surgical resection), complete MRI study including DWI at staging, and 
availability of the tumor specimen for histopathological review. Exclusion criteria were 
severe artifacts at DWI or postcontrast images, tumor size less than 6 cm3 (which would 
render ADC estimates less reliable), or predominantly cystic lesions (since ADC of cyst 
content is clinically uninteresting). In addition to DWI, a complete MRI study included at 
least T1-weighted sequences pre- and postcontrast medium administration. This was in 
order to enable exclusion of nonenhancing parts (likely necrotic parts) of tumor from the 
ADC analysis. 
Twenty patients were excluded due to the following: incomplete MRI study (n = 8); 
diagnostically relevant artifacts (n = 3); no histopathological specimen available for review 
(n = 3); lesion too small (n = 3); predominantly cystic (n = 2); non-Wilms' renal tumor (n = 1). 
The final study population consisted of the remaining 52 patients (mean age 2.6 years, 
range 1 months to 12.1 years, 24 males, Table 1). The preoperative treatment consisted of 4 
weeks of chemotherapy with vincristine and actinomycin D for localized tumors. Children 
with metastases at diagnosis received 6 weeks of preoperative therapy with three drugs, 
including doxorubicin, according to the guidelines of the SIOP-RT 2001 protocol. 
Table 1. Characteristics of Included Patients 
In 25 patients, complete diagnostic MRI including DWI was performed after the 
preoperative therapy, shortly before surgical resection for restaging purposes. 
Some of the scans had previously been included in a mathematical modeling study.[9] We 
used a clinically driven approach to investigate if whole-tumor ADC measurements could 
help in identifying blastemal predominant tumors. 
The flow diagram according to standards for reporting diagnostic accuracy studies (STARD) 
is illustrated in Fig. 
MRI Acquisition 
Abdominal MRI in our institution during the study period was performed with a 1.5T MRI 
system (Magnetom Avanto; Siemens, Erlangen, Germany). The imaging protocol consisted 
of axial and coronal T2-weighted short-tau inversion recovery, fat-suppressed axial pre- and 
postcontrast T1-weighted turbo spin-echo, and axial DWI. DWI was acquired with at least 
the following b-values: 0, 50, 250, 500, and 1000 s/mm2. The imaging parameters are 
displayed in Table 2. ADC maps were automatically generated by the scanner operating 
system. 
Table 2. Scan Parameters at 1.5T MRI for Suspected Renal Tumor and for Imaging of 
Nephroblastoma After Neoadjuvant Chemotherapy 
Children were awake, sedated, or under general anesthesia, depending on their ability to 
cooperate. All children were screened for contraindications for MRI, for use of intravenous 
contrast agents, and for intravenous hyoscine butylbromide. No oral contrast agents were 
used. Gadoterate meglumine (Dotarem; Guerbet Laboratories, Roissy, France) was 
administered at an intravenous dose of 0.05 mmol/kg body weight; 0.4 mg/kg body weight 
of hyoscine butylbromide (Buscopan, Boehringer Ingelheim, Bracknell, UK) was given 
intravenously to reduce peristaltic artifacts. 
Image Analysis 
The anonymized MR datasets were transferred to DICOM software Osirix v. 5.5.2 (Pixmeo 
SARL, Bernex, Switzerland). A pediatric radiologist (A.S.L. with 9 years of experience in body 
MRI), who was blinded to clinical patient data and histopathology reports, performed the 
ADC measurements. The pretreatment images were at the readers' disposal when analyzing 
the posttreatment images, in order to compare and identify the location of tumor. The 
reliability of this method had already been demonstrated to be sufficient,[12] and therefore 
it was deemed unnecessary to have more than one reader. 
Whole-Tumor ADC Measurements 
A freehand region of interest (ROI) was carefully drawn on the ADC map using the 
postcontrast and T2-weighted images to guide the outline of the entire tumor at each 
consecutive tumor-containing slice, excluding peritumoral edema. To reduce the partial 
voluming effect, we included the slices the where tumor area was >50% of the adjacent 
more central slice and where the tumor area was at least 3 cm3. 
Areas of tumor with no or very low enhancement were excluded from further analysis, 
because these are thought to represent necrosis, hemorrhage, or cystic elements. These 
components can skew the ADC location parameters if included.[12] This method was 
described in detail previously.[12] 
Whole-tumor ADC values before subtraction was documented in order to study the effect of 
subtraction. The DICOM software automatically calculated the tumor volume estimates 
from the whole-tumor ROIs. Viable portions of tumor were calculated by dividing the 
number of pixels after subtraction of less-enhancing parts of the lesions by the number of 
pixels before subtraction. 
Recent studies have shown that volume of blastema has prognostic value with respect to 
event-free and overall survival.[3] Therefore, we analyzed the volume of blastema in 
preoperative treated lesions and ADC parameters. The estimated volume of blastema 
(reference standard) was calculated by the following formula: volume provided by whole-
tumor ROI before subtraction × (1- proportion of chemotherapy induced changes at 
histopathology) × the proportion of blastema at histopathology. 
Histopathological Review 
One consultant pediatric histopathologist (N.J.S. with more than 15 years' experience with 
pediatric tumor histopathology) reviewed histological sections from the surgically resected 
tumors of all included patients. The percentage of chemotherapy-induced changes, 
percentage of stromal, epithelial, and blastemal elements, overall tumor type, and stage 
were recorded for every tumor, blinded to MRI findings. The SIOP-WT 2001 criteria for 
subtyping nephroblastoma were used (Table 3).[1] 
Table 3. Histological Criteria for Nephroblastoma Tumor Subtyping in SIOP WT 2001 
Statistical Analysis 
The Shapiro–Wilk test was used to check whether the variables tested could reasonable be 
assumed normally distributed. W more than 0.90 was considered to represent normal 
distribution. 
The Wilcoxon Rank test was used to test if the ADC median pre vs. ADC median post and 
ADC median with subtraction vs. without subtraction were significantly different. 
Potential associations between ADC parameters and proportions of histological subtypes 
were assessed with Pearson's or Spearman's rank correlation coefficient, depending on 
whether the parameters tested were normally distributed. 
The ADC values of tumors with >2/3 stromal histopathology were compared with the ADC 
values of the other subtypes using the Mann–Whitney U-test. In case the test revealed a 
significant difference, diagnostic performance was analyzed with construction a receiver 
operator characteristic (ROC) curve with calculation of the area under the curve (AUC) along 
with 95% confidence intervals (CIs). The ROC curve was used to determine the optimal AUC 
cutoff value with corresponding sensitivity and specificity. P < 0.05 was considered 
significant. SPSS v. 22 for Mac (Chicago, IL) was used for all statistical analysis. 
Results 
ADC With and Without Subtraction of Areas With No or Very Low Enhancement 
To assess if subtraction of areas with no or very little enhancement is needed in every 
lesion, we compared the ADC values before and after subtraction. 
The differences in whole-tumor median ADC at presentation before and after subtraction of 
less-enhancing parts ranged between –0.28 and 0.28 × 10−3 mm2/s, with a median 
difference of 0.009 × 10−3 mm2/s (54 lesions in 52 patients). In five patients the difference 
was more than 0.10 × 10−3 mm2/s. In 24 patients there was no difference. 
The differences before and after subtraction for median ADC after preoperative treatment 
were more distinct (25 lesions in 25 patients). The median difference was 0.09 × 10−3 
mm2/s (range –0.50 to 0.62 × 10−3 mm2/s). In eight patients there was no difference. In 
seven patients the difference was more than 0.10 × 10−3 mm2/s. 
Whole-Tumor MRI Parameters and Histopathological Response 
Change in size is often used to assess treatment response in oncology. Therefore, we 
studied the relation between volume change during preoperative treatment and 
chemotherapy-induced changes seen at histopathology. The median volume of pretreated 
lesions was 424.9 cm3 (range 10.7–1157.8, interquartile range [IQR] 447.7). After treatment 
the median volume of lesions was 204.5 cm3 (6.21–1208.0; IQR 209.9). The difference in 
volume (median 164.4 (–464.6-1023.8; IQR 190.3)) was not related to chemotherapy-
induced changes at histopathology (Spearman‘s’ r = 0.099; 95% CI –0.173–0.357, P = 0.637). 
The proportion of enhancing (viable) parts of lesions decreased after treatment (median 
viable portion at presentation 0.95 (range 0.65–1.00); IQR 0.14 and median viable portion 
after preoperative treatment 0.86 (range 0.25–1.00; IQR 0.31)). 
The enhancing portion after treatment showed a strong inverse relation with 
chemotherapy-induced changes at histopathology (r = –0.775; 95% CI –0.895 to –0.548, P < 
0.0005) 
Median ADC Before and After Preoperative Treatment 
To assess if we were able to measure treatment response other than shrinkage and 
necrosis, we analyzed the ADC parameters at presentation and after preoperative 
treatment after subtraction of the less-enhancing parts of lesions. The mean ADC of the 54 
whole-tumor median ADC at presentation was 0.945 × 10−3 mm2/s (SD 0.232; range 0.641-
1.416 × 10−3 mm2/s). In 25 of 54 lesions that were available for analysis after preoperative 
chemotherapy, the mean ADC was 1.342 × 10−3 mm2/s (SD 0.350; range 0.781–1.951 × 
10−3 mm2/s). ADC at presentation was significantly lower compared to ADC after 
preoperative treatment (Z –4.276, P < 0.0005) (Fig. 2). 
 
ADC Parameters and Histopathology Findings 
The distribution of median ADC after treatment per histopathological subtype is illustrated 
in Fig. 3, which also shows the distribution of the changes in median ADC after preoperative 
treatment by histopathology type. Figure 4 illustrates examples of histopathological 
subtypes with MRI appearances before and after preoperative treatment. 
However, only a few blastemal and epithelial predominant tumors were represented in this 
cohort. Therefore, we also studied the relation between the proportion of each 
histopathological component within the lesion and ADC parameters. 
Blastemal Histopathology 
With the small number of patients we included, there was no significant correlation 
between median ADC at presentation and the proportion of blastema (r = –0.248; 95% CI –
0.483–0.021, P = 0.070) (Table 4). However, the 25th percentile ADC and proportion of 
blastema in 54 lesions at staging showed a weak but significant correlation (r = –0.303; 95% 
CI –0.527 to –0.039, P = 0.026) (Table 4). Figure 5 shows the relationship of 25th percentile 
ADC at presentation and the proportion of blastema and epithelial subtype at 
histopathology. This plot illustrates the overlap in low ADC values between lesions with 
relative high blastemal and epithelial proportions. The correlation between the 25th 
percentile ADC and blastemal proportion in 25 lesions after treatment was not significant 
(r = –0.366; 95% CI –0.664 to –0.034, P = 0.072). 
Figure 4.  
A 6½-year-old girl presented with a large right-sided renal tumor, histopathologically proven 
nephroblastoma, blastemal predominant subtype. Subtracted postcontrast axial T1-W MR 
image (a) and corresponding axial ADC map (c) at presentation show a large, homogenous 
tumor with relatively low ADC value (median ADC 0.806 × 10−3 mm2/s; volume 707.1 cm3). 
After preoperative treatment (b,d) there is shrinkage of the lesion and an increase in 
median ADC value (volume 115.7 cm3; median ADC before subtraction: 0.935 × 10−3 
mm2/s, median ADC after subtraction 1.052 × 10−3 mm2/s; 25th% ADC after subtraction 
0.669 × 10−3 mm2/s). The areas of tumor with the very low ADC represent nonviable parts, 
as these areas show no contrast-enhancement on subtracted postcontrast axial T1-W MR 
image. MR images in a 1-month-old boy with right-sided renal nephroblastoma, epithelial 
subtype show the relatively low ADC (subtracted postcontrast axial T1-W image (e), ADC 
map (g); median ADC 0.664 × 10−3 mm2/s) at presentation. After treatment there is some 
shrinkage of the lesion, but with a limited shift in median ADC (subtracted postcontrast axial 
T1-W image (f), ADC map (h); median ADC 0.781 × 10−3 mm2/s). MR images in a 1-year-old 
girl with left-sided renal nephroblastoma, stromal subtype illustrates the relatively high ADC 
value at presentation (subtracted postcontrast axial T1-W image (i), ADC map (k); median 
ADC 1.401 × 10−3 mm2/s). There is an increase in size of the lesion after preoperative 
treatment with an increase in ADC value (subtracted postcontrast axial 
Scatterplot shows the relationship between 25th percentile ADC (×10−3 mm2/s) before 
preoperative treatment and percentage of blastemal (black dots) and epithelial (white dots) 
proportion of subtype at histopathology. This plot illustrates the overlap in low ADC values 
between lesions with relative high blastemal and epithelial proportions. 
With the limited included patients, there was no significant correlation between volume of 
blastema and 25th percentile ADC at presentation (r = –0.378; 95% CI –0.586 to –0.123, 
P = 0.062). 
Stromal Histopathology 
The median ADC showed a moderate correlation with proportion of stromal histology (at 
presentation: r = 0.401;95% CI 0.15–0.603, P = 0.003 and after treatment: r = 0.579; 95% CI 
0.239–0.792, P = 0.002) (Table 4). 
The median ADC after preoperative treatment in lesions with >2/3 stromal histopathology 
(n = 7) was significantly higher compared to the median ADC in the other tumors (P = 0.002). 
The ROC curve is shown in Fig. 6. The AUC was 0.895 (95% CI 0.773–1.00). Using an optimal 
cutoff value of 1.362 × 10−3 mm2/s, the sensitivity and specificity were 100% (95% CI 0.65–
1.00) and 78.9% (95% CI 0.57–0.92), respectively. 
Epithelial Histopathology 
The relatively limited shift in ADC after treatment appeared the best metric that correlated 
with proportion epithelial histopathology (r = –0.358; 95% CI –0.659–0.043, P = 0.073) (Table 
4). 
Discussion 
The results of our explorative, single-center study demonstrate that 25th percentile ADC is 
the most promising ADC metric related to identification of the proportion of blastema 
identified on histological evaluation. This finding is in concordance with previously reported 
results.[9] However, this weak correlation does not prove diagnostic usefulness. The 
existence of a linear relation disregards dispersion of observations, and any overall effect in 
a group of tumors cannot directly be extrapolated to an individual patient. If there is a 
significant overlap, for example, low ADC values that are seen in blastemal and in epithelial 
subtypes, the finding of low ADC may be of more limited clinical value even if there is a 
significant difference in the means. Therefore, the weak relationship demonstrated does 
not provide enough evidence that whole-tumor ADC measurements in routine clinical 
practice can act as a useful diagnostic tool to identify blastemal predominance. 
However, lesions with predominant stromal histology demonstrated a significant relation 
with the median ADC after preoperative chemotherapy. Furthermore, the ROC analysis 
showed that if an optimal cutoff value of 1.362 × 10−3 mm2/s is used, this parameter has 
high sensitivity (100%) and is relatively specific (78.9%). Stromal predominant tumors may 
be associated with a WT1 gene mutation frequently seen in bilateral disease.[13] The 
potential identification of stromal predominant tumors could therefore help in guiding 
preoperative therapy. 
Furthermore, our results support the need for subtraction of nonviable parts of tumors 
when measuring whole-tumor ADC values, especially relevant for posttreatment lesions, 
which are more heterogeneous and has a higher likelihood of containing nonviable 
elements. We showed that in 7 of 25 lesions the ADC difference before and after 
subtraction of cystic, hemorrhagic, or necrotic parts exceeded previously reported observer 
variability.[12] Therefore, such differences must be regarded as diagnostically relevant. The 
importance of subtracting nonviable parts of tumor is also highlighted in a recent report in 
pancreatic cancer, which used a selected area ROI method that visually excluded nonviable 
parts of lesions. This ADC metric was reported as the strongest marker for predicting 
improved survival during chemotherapy treatment. However, the observer variability of 
their method was not reported. 
Exclusion of the less-enhancing parts of the tumor allows measurement of preoperative 
therapy response of presumed cellular tumor elements. Our data further support previous 
reports[] that volume change in nephroblastoma is poorly related to response to 
chemotherapy, because shrinkage of tumor can be associated with high-risk histology types 
and conversely tumors may grow with differentiation. 
Our work builds on the valuable contributions of McDonald et al and Hales et al. Hales et al 
used a multi-Gaussian model for ADC analysis of different nephroblastoma subtypes. They 
were able to identify predominant histopathological cell types in nephroblastomas. We tried 
to translate this preclinical work to a clinical context. Our study used a clinically driven 
approach studying the best location parameter, measure treatment effects beyond necrosis, 
and relate ADC measurements to histopathological findings. 
This study has several limitations. First, it is a retrospective analysis of clinical datasets, with 
subsequent population bias. Second, related to the low incidence of this tumor, the number 
of included patients, especially in subgroups, was limited. Therefore, potential significant 
correlations between histopathological subtypes and ADC parameters could be obscured. 
Third, although we demonstrated a technically feasible method for measuring whole-tumor 
ADC after subtraction of less-enhancing parts, implementation in daily clinical practice could 
be hampered because outlining the whole-tumor volume is rather time-consuming. An 
alternative approach might be to place an ROI in a single section over the area of enhancing 
tumor with the most restricted diffusion; however, this method does probably not account 
for the full extent of ADC heterogeneity and is known to be less reliable. Fourth, although 
biopsy at presentation is performed as standard of care in our institution, whole-tumor 
histopathology was not available at presentation. Therefore, the comparison of ADC at 
presentation with the posttreatment histopathology is limited, as preoperative 
chemotherapy changes tumor histopathological features and distribution of subtypes. Fifth, 
we studied patients with localized and metastatic tumor as one cohort, although these 
groups receive different chemotherapeutic regimes. Finally, histopathological estimation of 
tumor composition is based on sampling rather than examination of the entire tumor and is 
therefore not perfectly objective. Further studies to assess direct correlation between ADC 
parameters and histopathological findings could further elucidate the potential role of 
diffusion-weighted imaging in nephroblastoma. 
In conclusion, whole-tumor ADC markers in nephroblastoma are correlated with stromal 
subtype histopathology; however, reliable differentiation between epithelial and blastemal 
predominant types using whole-tumor ADC measurements is probably not feasible, because 
both subtypes show marked diffusion restriction. 
